These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 39036877)

  • 41. Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2.
    Fischer A; Sellner M; Mitusińska K; Bzówka M; Lill MA; Góra A; Smieško M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669738
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Identification of Peptide Inhibitors of the Coronavirus 3CL Protease from a
    Duarte Filho LAMS; Yanaguibashi Leal CE; Bodet PE; Beserra de Alencar Filho E; Almeida JRGDS; Porta Zapata M; Achour O; Groult H; Gouveia Veloso CA; Viegas Júnior C; Bourgougnon N; Picot L
    Mar Drugs; 2024 May; 22(6):. PubMed ID: 38921555
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development.
    Zhu W; Shyr Z; Lo DC; Zheng W
    J Pharmacol Exp Ther; 2021 Aug; 378(2):166-172. PubMed ID: 33972366
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Re
    Karges J; Kalaj M; Gembicky M; Cohen SM
    Angew Chem Int Ed Engl; 2021 May; 60(19):10716-10723. PubMed ID: 33606889
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model.
    Vandyck K; Abdelnabi R; Gupta K; Jochmans D; Jekle A; Deval J; Misner D; Bardiot D; Foo CS; Liu C; Ren S; Beigelman L; Blatt LM; Boland S; Vangeel L; Dejonghe S; Chaltin P; Marchand A; Serebryany V; Stoycheva A; Chanda S; Symons JA; Raboisson P; Neyts J
    Biochem Biophys Res Commun; 2021 May; 555():134-139. PubMed ID: 33813272
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BRET-Based Self-Cleaving Biosensors for SARS-CoV-2 3CLpro Inhibitor Discovery.
    Hou N; Peng C; Zhang L; Zhu Y; Hu Q
    Microbiol Spectr; 2022 Aug; 10(4):e0255921. PubMed ID: 35758897
    [TBL] [Abstract][Full Text] [Related]  

  • 47. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease.
    Günther S; Reinke PYA; Fernández-García Y; Lieske J; Lane TJ; Ginn HM; Koua FHM; Ehrt C; Ewert W; Oberthuer D; Yefanov O; Meier S; Lorenzen K; Krichel B; Kopicki JD; Gelisio L; Brehm W; Dunkel I; Seychell B; Gieseler H; Norton-Baker B; Escudero-Pérez B; Domaracky M; Saouane S; Tolstikova A; White TA; Hänle A; Groessler M; Fleckenstein H; Trost F; Galchenkova M; Gevorkov Y; Li C; Awel S; Peck A; Barthelmess M; Schlünzen F; Lourdu Xavier P; Werner N; Andaleeb H; Ullah N; Falke S; Srinivasan V; França BA; Schwinzer M; Brognaro H; Rogers C; Melo D; Zaitseva-Kinneberg JI; Knoska J; Peña-Murillo GE; Mashhour AR; Hennicke V; Fischer P; Hakanpää J; Meyer J; Gribbon P; Ellinger B; Kuzikov M; Wolf M; Beccari AR; Bourenkov G; von Stetten D; Pompidor G; Bento I; Panneerselvam S; Karpics I; Schneider TR; Garcia-Alai MM; Niebling S; Günther C; Schmidt C; Schubert R; Han H; Boger J; Monteiro DCF; Zhang L; Sun X; Pletzer-Zelgert J; Wollenhaupt J; Feiler CG; Weiss MS; Schulz EC; Mehrabi P; Karničar K; Usenik A; Loboda J; Tidow H; Chari A; Hilgenfeld R; Uetrecht C; Cox R; Zaliani A; Beck T; Rarey M; Günther S; Turk D; Hinrichs W; Chapman HN; Pearson AR; Betzel C; Meents A
    Science; 2021 May; 372(6542):642-646. PubMed ID: 33811162
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Merbromin is a mixed-type inhibitor of 3-chyomotrypsin like protease of SARS-CoV-2.
    Chen J; Zhang Y; Zeng D; Zhang B; Ye X; Zeng Z; Zhang XK; Wang Z; Zhou H
    Biochem Biophys Res Commun; 2022 Feb; 591():118-123. PubMed ID: 35007835
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-HIV and anti-HCV small molecule protease inhibitors in-silico repurposing against SARS-CoV-2 M
    Sultan A; Ali R; Ishrat R; Ali S
    J Biomol Struct Dyn; 2022; 40(23):12848-12862. PubMed ID: 34569411
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis and Identification of Novel Potential Molecules Against COVID-19 Main Protease Through Structure-Guided Virtual Screening Approach.
    El Bakri Y; Anouar EH; Ahmad S; Nassar AA; Taha ML; Mague JT; El Ghayati L; Essassi EM
    Appl Biochem Biotechnol; 2021 Nov; 193(11):3602-3623. PubMed ID: 34324152
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of potential inhibitors targeting SARS-CoV-2 Mpro.
    Zhou WW; Li DS; Chen Y; You BQ; Zheng YF; Li Y; Si SY; Zhang J
    Eur Rev Med Pharmacol Sci; 2024 Sep; 28(18):4313-4325. PubMed ID: 39359203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fragment-based Drug Discovery Strategy and its Application to the Design of SARS-CoV-2 Main Protease Inhibitor.
    Jiang Y; Wu Y; Wang J; Ma Y; Yu H; Wang Z
    Curr Med Chem; 2024; 31(38):6204-6226. PubMed ID: 38529602
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
    Báez-Santos YM; St John SE; Mesecar AD
    Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors.
    Ghosh AK; Shahabi D; Yadav M; Kovela S; Anson BJ; Lendy EK; Bonham C; Sirohi D; Brito-Sierra CA; Hattori SI; Kuhn R; Mitsuya H; Mesecar AD
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641337
    [TBL] [Abstract][Full Text] [Related]  

  • 56. All-Trans Retinoic Acid Exhibits Antiviral Effect against SARS-CoV-2 by Inhibiting 3CLpro Activity.
    Morita T; Miyakawa K; Jeremiah SS; Yamaoka Y; Sada M; Kuniyoshi T; Yang J; Kimura H; Ryo A
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452533
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
    Goyal B; Goyal D
    ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CL
    Stille JK; Tjutrins J; Wang G; Venegas FA; Hennecker C; Rueda AM; Sharon I; Blaine N; Miron CE; Pinus S; Labarre A; Plescia J; Burai Patrascu M; Zhang X; Wahba AS; Vlaho D; Huot MJ; Schmeing TM; Mittermaier AK; Moitessier N
    Eur J Med Chem; 2022 Feb; 229():114046. PubMed ID: 34995923
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening.
    Sanachai K; Somboon T; Wilasluck P; Deetanya P; Wolschann P; Langer T; Lee VS; Wangkanont K; Rungrotmongkol T; Hannongbua S
    PLoS One; 2022; 17(6):e0269563. PubMed ID: 35771802
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.
    Gurard-Levin ZA; Liu C; Jekle A; Jaisinghani R; Ren S; Vandyck K; Jochmans D; Leyssen P; Neyts J; Blatt LM; Beigelman L; Symons JA; Raboisson P; Scholle MD; Deval J
    Antiviral Res; 2020 Oct; 182():104924. PubMed ID: 32896566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.